Search results
Results from the WOW.Com Content Network
Citalopram, sold under the brand name Celexa among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. [7] [10] It is used to treat major depressive disorder, obsessive compulsive disorder, panic disorder, and social phobia. [7] The antidepressant effects may take one to four weeks to occur. [7]
This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification.
[35] [29] However, the pathophysiology of Parkinson's disease is complex and multifacted, and MAO-B inhibitors may only slow the progression of the disease and do not halt it. [35] [29] The MAO-B inhibition by oral selegiline shows dosage dependence at typical therapeutic doses and below (i.e., ≤10 mg/day).
Monoamine oxidase inhibitors (MAOIs) are a class of drugs that inhibit the activity of one or both monoamine oxidase enzymes: monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). They are best known as effective antidepressants , especially for treatment-resistant depression and atypical depression . [ 1 ]
Vistaril (hydroxyzine) – an antihistamine for the treatment of itches and irritations, an antiemetic, as a weak analgesic, an opioid potentiator, and as an anxiolytic Vyvanse ( lisdexamfetamine ) – a pro-drug stimulant used to treat attention deficit hyperactivity disorder and binge eating disorder ; Vyvanse is converted into Dexedrine in vivo
Some research suggests that certain phenotypes of depression, such as those with anxiety, and "atypical" symptoms involving psychomotor retardation, weight gain and interpersonal sensitivity respond better to MAO inhibitors than other classes of anti-depressant. However the findings related to this have not been consistent. [43]
Rasagiline acts as an inhibitor of the enzyme monoamine oxidase (MAO) and hence is a monoamine oxidase inhibitor (MAOI). [2] More specifically, it is a selective inhibitor of monoamine oxidase B (MAO-B). [2] The drug is thought to work by increasing levels of the monoamine neurotransmitter dopamine in the brain. [2]
This is a list of investigational antidepressants, or drugs that are currently under development for clinical use in the treatment of depression but are not yet approved. . Specific indications include major depressive disorder, treatment-resistant depression, dysthymia, bipolar depression, and postpartum depression, among oth